Principal Investigator

​Carl D. Novina MD, PhD is an Associate Professor of Medicine at the Dana-Farber Cancer Institute & Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT. He received his M.D. from Columbia University, College of Physicians and Surgeons and his Ph.D. from Tufts University, Sackler School of Graduate Biomedical Sciences. He completed his postdoctoral fellowship at the Massachusetts Institute of Technology in the laboratory of Nobel Laureate Dr. Phillip Sharp.
 
Dr. Novina’s laboratory has made several important discoveries about the biology of noncoding RNAs, their dysregulation in cancers, and their development as biomedical tools. His recent work has been driven by the unmet clinical needs in cancer therapy. His laboratory has developed tools for epigenetic engineering and autologous T cell engineering for cancer immunotherapy. He has established numerous collaborations between industry partners and physicians to accelerate the translation of these tools to the clinic.
 
Dr. Novina is the recipient of numerous awards and honors including the Doris Duke Clinical Scientist Development Award, American Cancer Society Research Scholar Award, W.M. Keck Distinguished Young Scholars Award, Department of Defense Idea Award, The NCI Director’s Provocative Questions Award, and the National Science Foundation Collaborative Research Project Award. He is also the recipient of the prestigious NIH Director’s Pioneer Award, which funds high-risk research with transformative potential.